CIBC Asset Management Inc boosted its position in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 57.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 73,165 shares of the medical instruments supplier’s stock after buying an additional 26,668 shares during the period. CIBC Asset Management Inc’s holdings in Becton, Dickinson and Company were worth $14,199,000 as of its most recent SEC filing.
Other large investors also recently bought and sold shares of the company. Imprint Wealth LLC purchased a new stake in shares of Becton, Dickinson and Company in the third quarter valued at about $25,000. Steph & Co. raised its holdings in Becton, Dickinson and Company by 95.6% during the fourth quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 65 shares in the last quarter. Cornerstone Planning Group LLC lifted its position in Becton, Dickinson and Company by 463.3% in the third quarter. Cornerstone Planning Group LLC now owns 169 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 139 shares during the period. Accredited Wealth Management LLC lifted its position in Becton, Dickinson and Company by 77.8% in the third quarter. Accredited Wealth Management LLC now owns 160 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 70 shares during the period. Finally, WPG Advisers LLC boosted its holdings in Becton, Dickinson and Company by 64.2% in the 4th quarter. WPG Advisers LLC now owns 156 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 61 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.
Insider Activity at Becton, Dickinson and Company
In related news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $146.35, for a total value of $404,511.40. Following the sale, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $16,122,355.05. This represents a 2.45% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 2,913 shares of company stock valued at $426,806. 0.40% of the stock is owned by insiders.
Analysts Set New Price Targets
Becton, Dickinson and Company Stock Performance
BDX opened at $149.47 on Friday. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $187.35. The stock has a market cap of $41.18 billion, a P/E ratio of 37.84, a P/E/G ratio of 10.31 and a beta of 0.22. The stock’s 50 day simple moving average is $150.86 and its 200 day simple moving average is $175.71. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55.
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.13. The firm had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.Becton, Dickinson and Company’s revenue was up 5.2% on a year-over-year basis. During the same period in the previous year, the firm posted $3.35 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. As a group, equities analysts anticipate that Becton, Dickinson and Company will post 12.61 EPS for the current fiscal year.
Becton, Dickinson and Company Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th will be paid a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend is Tuesday, June 9th. Becton, Dickinson and Company’s payout ratio is 106.33%.
Becton, Dickinson and Company Profile
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.
BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.
Read More
- Five stocks we like better than Becton, Dickinson and Company
- The Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro Computer in Focus
- Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand
- Medtronic Bottoms, Healthy Rebound Ahead
- GitLab’s Price Recovery Gains Traction—Time to Get On Board?
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
